Israel’s Omnix (reported here previously) has been awarded €10.8 million in EU funding under the EIC Accelerator Programme, part of the EU’s Horizon 2020 research funding program. Omnix’s OMN6 peptide destroys the bacteria’s membrane, regardless of its resistance.

https://www.calcalistech.com/ctech/articles/0,7340,L-3889749,00.html

https://www.omnixmedical.com/omnix-medical-wins-e10-8m-in-eic-accelerator-funding/